"HSR21-061: Frequency of Oncologists (ONC) Office Visit and Caregiver Burden With Poly(ADP-ribose) Polymerase Inhibitor (PARPi) Versus Chemotherapy (CTX) Among Adult Patients (pts) With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC): Results From a Multi-Country Real-World (RW) Study" by Reshma Mahtani

Article

HSR21-061: Frequency of Oncologists (ONC) Office Visit and Caregiver Burden With Poly(ADP-ribose) Polymerase Inhibitor (PARPi) Versus Chemotherapy (CTX) Among Adult Patients (pts) With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC): Results From a Multi-Country Real-World (RW) Study

Journal of the National Comprehensive Cancer Network (2021)

Reshma Mahtani, Baptist Health South Florida
M.P. Lux
A. Niyazov
K. Lewis
L. Massey
A. Rider
A. Arondekar

Link

Disciplines

Medicine and Health Sciences

Publication Date

March 17, 2021

Citation Information

Reshma Mahtani, M.P. Lux, A. Niyazov, K. Lewis, et al.. "HSR21-061: Frequency of Oncologists (ONC) Office Visit and Caregiver Burden With Poly(ADP-ribose) Polymerase Inhibitor (PARPi) Versus Chemotherapy (CTX) Among Adult Patients (pts) With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC): Results From a Multi-Country Real-World (RW) Study" Journal of the National Comprehensive Cancer Network Vol. 19 Iss. 35 (2021)
Available at: http://works.bepress.com/reshma-mahtani/103/